Dashboard
Manage Tickers

MRKMerck & Co., Inc.

NYSE merck.com


$ 130.53 $ 1.05 (0.81 %)    

Friday, 21-Jun-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.84 $ -1.29 (-0.27 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.96 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 130.72
$ 129.83
$ 0.00 x 0
$ 0.00 x 0
$ 129.09 - $ 131.13
$ 97.23 - $ 132.31
17,182,704
na
331.09B
$ 0.32
$ 143.58
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

5-biotech-stocks-with-key-catalysts-this-week-merck-intellia-verona-and-more
5 Biotech Stocks With Key Catalysts This W...
06/24/2024 08:51:47

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments
Gilead Sciences Faces Wall Street Speculat...
06/21/2024 15:42:22

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-155-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 16:59:56

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.

cracking-the-code-understanding-analyst-reviews-for-merck--co
Cracking The Code: Understanding Analyst R...
06/18/2024 21:00:57

competitor-analysis-evaluating-merck-amp-co-and-competitors-in-pharmaceuticals-industry
Competitor Analysis: Evaluating Merck &amp...
06/18/2024 15:00:37

covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment
Covid-19 Pharma Stars Continue Their Quest...
06/18/2024 14:19:12

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-155-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 12:08:42

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.

fda-approves-mercks-pneumococcal-vaccine-as-first-shot-designed-for-adults
FDA Approves Merck's Pneumococcal Vaccine ...
06/18/2024 12:05:42

The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains ...

Core News & Articles
FDA Approves CAPVAXIVE, Sixth Product Usin...
06/18/2024 12:03:40

merck-shares-are-trading-higher-after-the-fda-approved-capvaxive-for-the-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults
Merck shares are trading higher after the ...
06/18/2024 11:39:14

fda-approves-capvaxive-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults
FDA Approves CAPVAXIVE For Prevention Of I...
06/17/2024 21:31:48

CAPVAXIVE (V116) is specifically designed for adults and covers serotypes responsible for approximately 84% of invasive pneumoc...

fda-approves-mercks-keytruda-plus-carboplatin-paclitaxel-as-treatment-for-adult-patients-with-primary-advanced-or-recurrent-endometrial-carcinoma
FDA Approves Merck's KEYTRUDA Plus Carbopl...
06/17/2024 21:15:49

KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with prim...

merck--co-says-fda-approves-pembrolizumab-with-chemotherapy-for-primary-advanced-or-recurrent-endometrial-carcinoma-recommended-pembrolizumab-dose-is-200mg-every-3-weeks-or-400mg-every-6-weeks-until-disease-progression-unacceptable-toxicity-or-up-to-24-months
Merck & Co Says FDA Approves Pembrolizumab...
06/17/2024 16:32:03

- Reuters

merck--co-unusual-options-activity-for-june-14
Merck & Co Unusual Options Activity For Ju...
06/14/2024 18:15:51

how-is-the-market-feeling-about-merck--co
How Is The Market Feeling About Merck & Co?
06/11/2024 18:00:16

merck-exec-says-co-very-much-focused-on-the-second-third-generation-opportunities-in-cardiometabolic-drugs-focused-on-small-molecule-orals-versus-injectables-in-the-cardiometabolic-drug-market
Merck Exec Says Co "Very Much Focused On T...
06/11/2024 14:42:58

- Goldman Sachs Conf

merck-exec-says-co-continues-to-expect-deals-up-to-15b-with-focus-on-oncology
Merck Exec Says Co Continues To Expect Dea...
06/11/2024 14:16:03

- Goldman Sachs Conf

nike-merck-general-motors-and-more-cnbcs-final-trades
Nike, Merck, General Motors, And More: CNB...
06/10/2024 12:14:30

Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of ...

market-whales-and-their-recent-bets-on-mrk-options
Market Whales and Their Recent Bets on MRK...
06/07/2024 20:01:20

Core News & Articles
CNBC Halftime Report Final Trades: Nike, M...
06/07/2024 17:00:45

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)